SLC9A1 and acute myeloid leukemia: A notable observation in this study is the heterogeneity of AML cell responses to venetoclax–HMA co-treatment: while THP-1 cells exhibited pronounced synergy, U-937 cells were unresponsive, indicating that NHE1 activation is not a universal driver of venetoclax resistance.